While Raybiotech recently released their 2000 target antibody array, a publication from “The Scientist” highlighted the benefit of these High-density multiplexed technology in biomarker discovery. As a perfect complement to traditional techniques like Mass Spectrometry, these antibody arrays provide an interesting alternative for low abundance targets, with a sensitive and high throughput approach. tebu-bio laboratories has been appointed by RayBiotech as one of the 3 companies worldwide to perform contract research on these arrays, and can take your project on board from sample processing to data analysis. This post summarizes the services available, from protein profiling, to phosphorylation and glycosylation studies, including biostatistics support. It’s worth noting that all the arrays listed are compatible with most laser scanners and can be processed in any lab.

In new drug development pipelines, there is an increasing trend to switch from “small” to “large” molecules (also known as biologics). While the FDA guidance was quite specific with their recommendations for small molecules ADME-Tox studies, there is not much currently published for these large molecules.

The Japanese PDMA guidelines 2019 issue refers to some specificity regarding their internalization and degradation pathway. They are also well known to be prone to trigger cytokine release. The so called “cytokine storm” is one of the major toxicity events to be feared.

To support R&D projects around Biologics development, I have illustrated in this post what tebu-bio can offer in terms of reagents and services, including tools to monitor cytokine release (blood derivatives and cytokine multiplex assays), and reagents to help decipher their mechanism of action and catabolism.

Alone, or in combination with other therapies, Immuno-Oncology (I-O) appears currently as one of the most promising research fields to fight cancer. Nevertheless, developing breakthrough therapies to fully harness the immune system to fight diseased cells remain quite challenging.

To help researchers solve these hurdles, we have selected a complete offer of innovative and robust reagents and services. In this post, I wanted to highlight 6 Immuno-Oncology “must-haves” to facilitate your R&D projects.

In a previous post, I introduced a complete panel of ready-to-use specialized media for smooth muscle primary cells culture. Produced by Cell Applications, a GMP certified manufacturer of primary cells distributed by tebu-bio in Europe, these media were originally designed for Cell Applications own primary cells culture. However, many researchers isolating their own cells are using them to benefit from the expertise of a primary cell manufacturer and to use thoroughly QC tested media. Here, I invite you to look at a new selection for popular primary cell types, from skeletal muscle cells to synoviocytes, endothelial cells to pre-adipocytes. Have a read and find the one you need!